Records 1 - 30
| Concurrent TP53 mutations predict a poor prognosis of EGFR-mutant NSCLCs treated with TKIs: An updated systematic review and meta-analysis.
Oncology letters 2022 Nov 24 (5): 384.
Lan Bo, Zhao Na, Du Kang, Leng Baola
| A large-scale prospective concordance study of plasma- and tissue-based next-generation targeted sequencing for advanced non-small cell lung cancer (LC-SCRUM-Liquid).
Clinical cancer research : an official journal of the American Association for Cancer Research 2022 Oct .
Sugimoto Akira, Matsumoto Shingo, Udagawa Hibiki, Itotani Ryo, Usui Yuko, Umemura Shigeki, Nishino Kazumi, Nakachi Ichiro, Kuyama Shoichi, Daga Haruko, Hara Satoshi, Miyamoto Shingo, Kato Terufumi, Sakakibara-Konishi Jun, Tabata Eriko, Nakagawa Taku, Kawaguchi Tomoya, Sakai Tetsuya, Shibata Yuji, Izumi Hiroki, Nosaki Kaname, Zenke Yoshitaka, Yoh Kiyotaka, Goto Koic
| Age does matter in adolescents and young adults vs. older adults with lung adenocarcinoma: A retrospective analysis comparing clinical characteristics and outcomes in response to systematic treatments.
Oncology letters 2022 Oct 24 (4): 362.
Zhou Lin, Li Huiwu, Yang Shuh
| Baseline anemia predicts a poor prognosis in patients with non-small cell lung cancer with epidermal growth factor receptor mutations: a retrospective study.
BMC pulmonary medicine 2022 Oct 22 (1): 381.
Wei Jingwen, Xiang Jing, Hao Yue, Si Jinfei, Wang Wenxian, Li Fangyin, Song Zheng
| Differentiating EGFR from ALK mutation status using radiomics signature based on MR sequences of brain metastasis.
European journal of radiology 2022 Oct 155 110499.
Li Ye, Lv Xinna, Wang Bing, Xu Zexuan, Wang Yichuan, Gao Shan, Hou Dail
| EGFR Mutation-Positive Unresectable Stage III Non-Squamous Lung Cancer is Associated with a High Incidence of Brain Metastasis.
Cancer research and treatment 2022 Oct .
Kim Hongsik, Park Sehhoon, Jung Hyun Ae, Sun Jong-Mu, Lee Se-Hoon, Ahn Jin Seok, Ahn Myung-
| ERBB2 exon 20 insertions are rare in Brazilian non-small cell lung cancer.
Thoracic cancer 2022 Oct .
de Oliveira Cavagna Rodrigo, Zaniolo Beatriz Garbe, de Paula Flávia Escremim, Berardinelli Gustavo Noriz, Santana Iara, da Silva Eduardo Caetano Albino, Dias Josiane Mourão, Jacinto Alexandre Arthur, da Nóbrega Oliveira Rachid Eduardo Noleto, de Marchi Pedro, Leal Letícia Ferro, Reis Rui Manu
| PIK3CA mutations associated with a poor postoperative prognosis in patients with pulmonary pleomorphic carcinoma: a retrospective cohort study.
BMC cancer 2022 Oct 22 (1): 1066.
Kojima Kensuke, Imai Saki, Samejima Hironobu, Fujiwara Ayako, Tokunaga Toshiteru, Yoon Hyungeun, Okishio Kyoic
| Prognostic biomarkers correlated with immune infiltration in non-small cell lung cancer.
FEBS open bio 2022 Oct .
Xu Fei, Cui Wen-Qiang, Liu Cun, Feng Fubin, Liu Ruijuan, Zhang Jingtao, Sun Chang-Ga
| Correlations of switch/sucrose nonfermentable complex mutations with clinical outcomes in advanced non-small cell lung cancer.
Thoracic cancer 2022 Sep .
Chang Geyun, Li Weihua, Bai Hua, Duan Jianchun, Wang Zhijie, Du Xinyang, Yu Ruofei, Wang Yaxi, Wang Minghao, Zhu Yixiang, Zhang Xue, Li Li, Wan Rui, Wang J
| Efficacy and potential resistance mechanisms of afatinib in advanced non-small cell lung cancer patients with EGFR G719X/L861Q/S768I.
Cancer 2022 Sep .
Pang Lan-Lan, Gan Jia-Di, Tan Jia-Rong, Huang Yi-Hua, Liao Jun, Liang Wei-Ting, Deng Peng-Bo, Fang Wen-Fe
| Efficacy of epidermal growth factor receptor tyrosine kinase inhibitors in patients with recurrent non-small cell lung cancer after definitive concurrent chemoradiation or radiotherapy.
Journal of cancer research and clinical oncology 2022 Sep .
Hyung Jaewon, Yoon Hyunseok, Choi Chang-Min, Yoon Shinkyo, Lee Dae Ho, Kim Sang-We, Kim Hyeong-Ryul, Kim Su Ssan, Song Si Yeol, Lee Jae Che
| EGFR mutation prevalence, real-world treatment patterns, and outcomes among patients with resected, early-stage, non-small cell lung cancer in Canada.
Lung cancer (Amsterdam, Netherlands) 2022 Sep 173 58-66.
Sara Kuruvilla M, Liu Geoffrey, Syed Iqra, Gwadry-Sridhar Femida, Sheffield Brandon S, Sachdeva Robin, Pencz Alec, Zhan Luna, Hueniken Katrina, Patel Devalben, Balaratnam Karmugi, Khan Khaleeq, Grant Benjamin, Noy Shawna, Singh Karan, Liu Linda, Rakibuz-Zaman Muhammad, Moldaver Daniel, Kate Shanahan Mary, Cheema Parneet
| EGFR-TKI re-administration after osimertinib failure in T790M mutation loss cases with re-biopsy.
Investigational new drugs 2022 Sep .
Ogusu Shinsuke, Ariyasu Ryo, Akita Takahiro, Kiritani Ayu, Tsugitomi Ryosuke, Amino Yoshiaki, Uchibori Ken, Kitazono Satoru, Yanagitani Noriko, Nishio Mako
| Fibroblast subsets in non-small cell lung cancer: associations with survival, mutations, and immune features.
Journal of the National Cancer Institute 2022 Sep .
Pellinen Teijo, Paavolainen Lassi, Martín-Bernabé Alfonso, Papatella Araujo Renata, Strell Carina, Mezheyeuski Artur, Backman Max, La Fleur Linnea, Brück Oscar, Sjölund Jonas, Holmberg Erik, Välimäki Katja, Brunnström Hans, Botling Johan, Moreno-Ruiz Pablo, Kallioniemi Olli, Micke Patrick, Östman Ar
| Pre-radiotherapy systemic immune inflammation index associated with overall survival in patients with advanced EGFR mutant non-small cell lung cancer receiving thoracic radiotherapy.
Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico 2022 Sep .
Chen Dujuan, Qin Hongyue, Deng Guangchuan, Wang Qi, Wang Haiyong, Liu Xij
| Results from the IMpower132 China cohort: Atezolizumab plus platinum-based chemotherapy in advanced non-small cell lung cancer.
Cancer medicine 2022 Sep .
Lu Shun, Fang Jian, Wang Ziping, Fan Yun, Liu Yunpeng, He Jianxing, Zhou Jianying, Hu Jie, Xia Jinjing, Liu Wenxin, Shi Jane, Yi Jing, Cao Lej
| RET fusions as primary oncogenic drivers and secondary acquired resistance to EGFR tyrosine kinase inhibitors in patients with non-small-cell lung cancer.
Journal of translational medicine 2022 Sep 20 (1): 390.
Wang Chunyue, Zhang Zhenlong, Sun Yulan, Wang Song, Wu Mengmeng, Ou Qiuxiang, Xu Yang, Chen Zhiming, Shao Yang, Liu Hong, Hou Peife
| Tumoral PD-L1 does not impact time to treatment discontinuation in EGFR mutated non-small cell lung cancer patients treated with EGFR tyrosine kinase inhibitor-a Danish cohort study.
Translational lung cancer research 2022 Sep 11 (9): 1796-1808.
Dissing Julie Gabe, Ulhøi Maiken Parm, Sorensen Boe Sandahl, Meldgaard Pet
| A Multi-Center Real-World Experience of IMpower150 in Oncogene Driven Tumors and CNS Metastases.
Clinical lung cancer 2022 Aug .
Itchins Malinda, Ainsworth Hannah, Alexander Marliese, Dean Samantha, Dharmaraj Devi, Pavlakis Nick, Clarke Stephen J, Brown Chris, Torres Javier, Saqib Ayesha, Ladwa Rahul, O'Byrne Kenneth, Moore Melissa, Yip Po Yee, Solomon Ben, John Tom, Kao Steven, Mitchell Paul, Parakh Sag
| Advances in the treatment of postoperative recurrence of non-small cell lung cancer and their impact on survival in Asian patients.
The Journal of thoracic and cardiovascular surgery 2022 Aug .
Hashimoto Kohei, Ariyasu Ryo, Ichinose Junji, Matsuura Yosuke, Nakao Masayuki, Amino Yoshiaki, Uchibori Ken, Kitazono Satoru, Yanagitani Noriko, Okumura Sakae, Nishio Makoto, Mun Mingy
| High Tumor Mutation Burden Is Associated with Poor Clinical Outcome in EGFR-Mutated Lung Adenocarcinomas Treated with Targeted Therapy.
Biomedicines 2022 Aug 10 (9): .
Sung Ji-Youn, Park Dong-Won, Lee Seung-Hye
| Real-World Study of Osimertinib in Korean Patients with Epidermal Growth Factor Receptor T790M Mutation-Positive Non-Small Cell Lung Cancer.
Cancer research and treatment 2022 Aug .
Lee Jang Ho, Kim Eun Young, Park Cheol-Kyu, Lee Shin Yup, Lee Min Ki, Yoon Seong-Hoon, Lee Jeong Eun, Lee Sang Hoon, Kim Seung Joon, Lee Sung Yong, Lim Jun Hyeok, Jang Tae-Won, Jang Seung Hun, Lee Kye Young, Lee Seung Hyeun, Yang Sei Hoon, Park Dong Won, Park Chan Kwon, Kang Hye Seon, Yeo Chang Dong, Choi Chang-Min, Lee Jae Che
| Retrospective analysis of independent predictors of progression-free survival in patients with EGFR mutation-positive advanced non-small cell lung cancer receiving first-line osimertinib.
Thoracic cancer 2022 Aug .
Teranishi Shuhei, Sugimoto Chihiro, Nagaoka Satoshi, Nagayama Hirokazu, Segawa Wataru, Miyasaka Atsushi, Hiro Shuntaro, Kajita Yukihito, Maeda Chihiro, Kobayashi Nobuaki, Yamamoto Masaki, Kudo Makoto, Kaneko Takes
| Analytical and clinical validation of a custom 15-gene next-generation sequencing panel for the evaluation of circulating tumor DNA mutations in patients with advanced non-small-cell lung cancer.
PloS one 2022 17 (10): e0276161.
Chow Yock Ping, Zainul Abidin Norziha, Kow Ken Siong, Tho Lye Mun, Wong Chieh L
| Comparison of real-world data (RWD) analysis on efficacy and post-progression outcomes with pembrolizumab plus chemo vs chemo alone in metastatic non-squamous non-small cell lung cancer with PD-L1 < 50.
Frontiers in oncology 2022 12 980765.
Attili Ilaria, Valenza Carmine, Santoro Celeste, Antonarelli Gabriele, Trillo Aliaga Pamela, Del Signore Ester, Catania Chiara, Spitaleri Gianluca, Passaro Antonio, de Marinis Filip
| Computed tomography-based radiomics quantification predicts epidermal growth factor receptor mutation status and efficacy of first-line targeted therapy in lung adenocarcinoma.
Frontiers in oncology 2022 12 985284.
Jiang Meilin, Yang Pei, Li Jing, Peng Wenying, Pu Xingxiang, Chen Bolin, Li Jia, Wang Jingyi, Wu L
| Genomic landscape of lung adenocarcinomas in different races.
Frontiers in oncology 2022 12 946625.
Shi Huashan, Seegobin Karan, Heng Fei, Zhou Kexun, Chen Ruqin, Qin Hong, Manochakian Rami, Zhao Yujie, Lou Yany
| Genomic landscape of lung cancer in the young.
Frontiers in oncology 2022 12 910117.
Ruiz Rossana, Galvez-Nino Marco, Roque Katia, Montes Jaime, Nuñez Maria, Raez Luis, Sánchez-Gambetta Sergio, Jaúregui Sandra, Viale Sandra, Smith Edward S, Pinto Joseph A, Mas Lu
| Rare EGFR E709-T710delinsX: Molecular characteristics and superior response to afatinib treatment in NSCLC patients.
Lung cancer (Amsterdam, Netherlands) 2022 10 172 117-123.
Huang Yihua, Xu Chunwei, Sun Yuanliang, Wang Wenxian, Li Xingya, Liao Jun, Pang Lanlan, Zeng Liang, Li Juan, Wang Xihua, Zhang Qi, Xie Zhanhong, Xiao Lin, Gan Jiadi, Fang Wenfe